Nexstim PLC is taking its neuromodulation depression therapy to the Australian market following regulatory approval.
The Finnish company has received a medical device licence from the Australian Government Department of Health, which allows it to start marketing and selling the NBT system for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?